ExpreS2ion Biotech (One-pager): Market value below cash balance

Together with ExpreS2ion Biotechnologies' CEO, Bent Frandsen, we looked back at the main achievements in 2024, which was the first year of implementing the new strategy. The company has focused on leveraging the platform to advance assets with shorter development timelines, and it has also been a year with good progress in the pipeline. In the interview, you can hear more about the progress of the breast cancer candidate, external validation through partnerships, and lastly which milestones investors should look out for in 2025.

Today, ExpreS2ion Biotechnologies’ CEO Bent U. Frandsen and CFO Keith Alexander presented the results and update on business for the third quarter of 2024. Furthermore, they gave some insight into the latest developments in the pipeline including the term sheet agreement on the malaria candidate and progress on the CMV candidate.

ExpreS2ion Biotechnologies is expected to release its Q3 2024 results on 14 November 2024. Later the same day at 11:00, the company’s CEO Bent U. Frandsen and CFO Keith Alexander will take a deeper dive into the results and achievements during the period in an online live presentation. The management presentation will be followed by a Q&A session.